Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:43 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1481
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 733–744 of 1,481 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

NCT03180502
Site status not listed — check the official record
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Active, not recruiting Phase 3 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133
Site status not listed — check the official record
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
51
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Active, not recruiting Phase 2 Interventional Results available

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

NCT02912572
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Avelumab, Talazoparib, Axitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195
Status at this site: Recruiting
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ulixertinib, Ruxolitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

NCT05415072
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
DYP688
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
Site status not listed — check the official record
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting Phase 2 Interventional

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811
Status at this site: Recruiting
View directory record Official record
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07540338
Status at this site: Recruiting
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
AL001, Lithium carbonate
Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797
Status at this site: Recruiting
View directory record Official record
Conditions
Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions
Plixorafenib
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
8 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Not yet recruiting Not applicable Interventional

Biodegradable Magnesium Screws for Unstable Ankle Fracture Surgery

NCT07693933
Site status not listed — check the official record
View directory record Official record
Conditions
Ankle Fractures, Syndesmotic Injury
Interventions
RemeOs Magnesium-Based Biodegradable Screw
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 4:43 AM EST
Recruiting Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

NCT07078383
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic, Aneurysmal Disease, Aorta, Thoracic Pathologies
Interventions
Rapidlink
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 1, 2026, 4:43 AM EST

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.